Catalog No.: PC-60692Not For Human Use, Lab Use Only.
BML-281 (CAY10603) is a potent, selective HDAC6 inhibitor with IC50 of 0.002 nM, weakly inhibits HDAC3 (IC50=0.42 nM) and >50,000-fold selectivity over HDAC1/2/8/10.
BML-281 (CAY10603) is a potent, selective HDAC6 inhibitor with IC50 of 0.002 nM, weakly inhibits HDAC3 (IC50=0.42 nM) and >50,000-fold selectivity over HDAC1/2/8/10.
BML-281 (CAY10603) blocks pancreatic cancer cell growth with IC50 of <1 uM.
BML-281 (CAY10603) selectively reduces lamina propria B-cell infiltrate and suppresses CD19+ B lymphocyte influx into DSS-inflamed lamina propria, elicits broad-spectrum anti-inflammatory effects in DSS-induced colitis in mice.
